Aclarion Publishes CEO Letter; Notes Q3 Scan Volumes Up 85% YoY And Up 117% YtD

Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the Company’s momentum and value-creating priorities for the quarter ended September 30, 2026.

"The third quarter was a strong one for Aclarion, reflecting the growing interest among physicians in what Nociscan can offer their patients with chronic low back pain," said Brent Ness, Chief Executive Officer of Aclarion. "Scan volumes grew 85% year-over-year and 117% for the first nine months of 2026, and our clinical program is advancing on multiple fronts. The European Spine Journal publication adds to our growing evidence base, and CLARITY is now enrolling at eleven sites under revised criteria designed to accelerate recruitment and strengthen the study's real-world applicability."

The letter highlights Aclarion’s continued commercial traction and an expanding clinical evidence base which will be instrumental in supporting reimbursement initiatives in both the United Kingdom and the United States. The CEO update also highlights the Company’s ongoing commitment to the CLARITY clinical trial with updated inclusion/exclusion criteria to accelerate recruitment. In addition, the Company maintained a strong balance sheet with disciplined capital allocation and investments to create sustainable shareholder value.

The full CEO Shareholder Letter is available on the company’s website.